Carotid Artery Surgery — CEA, CAS and TCAR Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Carotid artery surgery encompasses a group of interventional procedures targeting the internal carotid artery (ICA) at the point of its bifurcation from the common carotid artery in the neck — one of the commonest sites of atherosclerotic plaque formation in the body. Carotid stenosis is responsible for approximately 15–20% of all ischaemic strokes, typically by embolism of plaque fragments or thrombotic material from the diseased artery into the cerebral circulation, causing transient ischaemic attacks (TIAs) or completed strokes.

The principle of carotid artery surgery is straightforward: remove or bypass the stenotic plaque before it causes an embolic stroke, when the patient has already had a warning event (TIA or minor stroke) or when the degree of narrowing is so severe that the risk of spontaneous stroke is high enough to justify intervention.

Three main interventional strategies exist. Carotid endarterectomy (CEA) is the traditional open surgical technique, in which the carotid artery is opened and the plaque mechanically removed under direct vision. Carotid artery stenting (CAS) is an endovascular approach in which a balloon-expandable or self-expanding metal stent is deployed across the stenosis via a catheter introduced through the femoral artery, with a distal embolic protection device to capture debris. Transcarotid arterial revascularisation (TCAR) is a hybrid procedure combining surgical access to the common carotid artery with endovascular stenting and direct carotid flow reversal during the procedure to minimise cerebral embolisation.

The decision between these approaches is driven by the degree and symptom status of carotid stenosis, anatomical considerations, patient age and comorbidities, and an evidence base from multiple landmark randomised trials conducted over 35 years. Vascular surgeons and neurointerventionists work jointly within TIA clinic and stroke MDT frameworks to make these decisions.

Carotid artery intervention is considered across several clinical presentations:

• Symptomatic high-grade stenosis (70–99%): Patients with recent TIA or non-disabling ischaemic stroke ipsilateral to a carotid stenosis of 70–99% (NASCET criteria, measured at the minimum lumen diameter compared to the distal ICA) represent the strongest indication for urgent CEA. The absolute risk reduction of 17% over 5 years and number needed to treat (NNT) of 6 from the NASCET trial represents one of the most compelling benefits of any surgical intervention in medicine. Intervention should occur within 14 days of the index event — ideally within 48–72 hours — to capture maximum benefit when stroke risk is highest.
• Symptomatic moderate stenosis (50–69%): The NASCET and ECST trials demonstrated significant but more modest benefit from CEA in this group. Benefit is particularly concentrated in men, patients aged over 75 years, and those with hemispheric (rather than ocular) symptoms, cortical infarction on imaging, and irregular plaque morphology. Decision-making is individualised, weighing surgical risk against expected benefit.
• Asymptomatic high-grade stenosis (60–99%): For patients with severe carotid stenosis who have not had a TIA or stroke, the benefit of intervention over optimal medical therapy (OMP) is smaller and more contentious. The ACST-2 trial (2021, N=3,625) demonstrated equivalent 5-year outcomes between CEA and CAS for asymptomatic stenosis, and found perioperative risk was approximately 1%. However, stroke rates on modern OMP (high-intensity statins, dual antiplatelet therapy, blood pressure control) are now so low that the net benefit of prophylactic surgery in asymptomatic patients is increasingly debated. The ECST-2 trial is ongoing, comparing intervention to OMP in lower-risk asymptomatic patients.
• Carotid restenosis: In-stent restenosis after CAS and recurrent stenosis after CEA may be treated by repeat CEA (if technically feasible), CAS, or TCAR, with the approach dictated by the mechanism and anatomy of restenosis.
• Radiation-induced carotid stenosis: A late complication of neck radiotherapy (for lymphoma, head and neck cancer), radiation-induced carotid disease is a high-risk anatomy for CEA (difficult dissection, poor tissue quality, wound healing problems). CAS or TCAR are often preferred in this setting.

Appropriate patient selection is the most important determinant of outcome from carotid intervention. The benefit of CEA or CAS over medical therapy alone is only realised if the perioperative stroke and death risk is sufficiently low to justify proceeding.

Anatomical assessment: Carotid stenosis degree is assessed by duplex carotid ultrasound (primary screening tool), CT angiography or MR angiography (for anatomical planning and aortic arch assessment before CAS). The NASCET method of stenosis measurement (distal ICA as denominator) is used universally for trial-based decision making; ECST measurements (carotid bulb as denominator) give systematically higher percentages for the same lesion.

Timing after the index event: The highest stroke risk in symptomatic carotid stenosis is in the first 48–72 hours after TIA. Urgent CEA within this window — previously considered high-risk due to concerns about transforming ischaemic infarcts haemorrhagic — has been demonstrated in registry studies to be safe when the infarct is small and the patient is neurologically stable. NICE guidelines recommend CEA within 14 days of symptom onset for eligible patients. Early CEA (within 48–72 hours) is preferred at specialist centres for patients with TIA or minor stroke without large established infarct on DWI-MRI.

Perioperative risk stratification: Contraindications to CEA include complete ICA occlusion (no plaque to remove), severe cardiac disease (recent MI under 6 weeks, unstable angina, severe heart failure), active systemic infection, large recent cerebral infarct (increased haemorrhagic transformation risk), and limited life expectancy from malignancy. High surgical risk features that may favour CAS over CEA include prior neck surgery or radiation, contralateral laryngeal nerve palsy, high carotid bifurcation above C2 vertebra, and severe contralateral carotid occlusion.

Age and CAS vs CEA choice: Multiple randomised trials (ICSS, CREST, SPACE) have consistently shown that CAS carries a higher periprocedural stroke rate than CEA in older patients (over 70 years), attributable to increased aortic arch calcification and tortuosity causing more embolic events during catheter manipulation. CEA is strongly preferred in patients over 70 years with symptomatic stenosis. CAS is preferred in patients under 70 with high surgical risk anatomy.

Carotid Endarterectomy (CEA): The standard open surgical approach. Under general or local cervical block anaesthesia, the carotid artery is exposed in the anterior neck, clamped proximally and distally, and opened longitudinally (arteriotomy). The atherosclerotic plaque is meticulously dissected from the arterial wall under magnification. The endpoint of endarterectomy is confirmed to be smooth and well-adherent. The arteriotomy is then closed.

Patch Angioplasty versus Primary Closure: The EVEREST randomised trial and multiple Cochrane meta-analyses have consistently demonstrated that closing the arteriotomy with a patch (Dacron, PTFE, bovine pericardium, or autologous vein) is superior to direct primary closure. Patch closure reduces the rates of perioperative ICA occlusion, restenosis at 1 year, and ipsilateral stroke. Patch closure is now strongly recommended as the standard technique for CEA, with primary closure reserved for large-calibre arteries where the lumen risk from primary suture is negligible.

Shunting — Routine versus Selective: A carotid shunt maintains cerebral perfusion during the period of carotid clamping. The debate between routine shunting (all patients) and selective shunting (only those who demonstrate cerebral ischaemia during clamping) has not been resolved by randomised evidence. Selective shunting is guided by real-time monitoring: continuous EEG is the most widely used monitor (new ipsilateral slow-wave or amplitude suppression suggests ischaemia); intraoperative transcranial Doppler (TCD) monitoring of MCA blood flow velocity provides an alternative. Either approach is acceptable; choice depends on surgical preference and available monitoring.

CEA under Local versus General Anaesthesia: The landmark GALA trial (Lewis et al., Lancet 2008, N=3,526) randomised patients to CEA under local or general anaesthesia and found no significant difference in 30-day stroke, MI, or death rates between the two approaches. Both techniques are acceptable; local cervical block anaesthesia allows continuous neurological monitoring of the awake patient during carotid clamping, potentially replacing the need for EEG or TCD shunt monitoring, and may be preferable in patients with severe cardiorespiratory disease where general anaesthesia risk is elevated.

Carotid Artery Stenting (CAS): Performed via femoral artery access under local anaesthesia and sedation, with a distal embolic protection device (EPD) deployed beyond the stenosis before dilating and stenting. CAS avoids a neck incision and cranial nerve risk and enables intervention in anatomically inaccessible lesions. The ICSS and CREST trials established that CAS carries a significantly higher risk of periprocedural minor stroke compared to CEA, particularly in older patients (over 70 years), though long-term outcomes converge. The ACST-2 trial (2021) found equivalent 5-year outcomes for CEA versus CAS in asymptomatic patients treated at expert centres.

Transcarotid Arterial Revascularisation (TCAR): A hybrid technique involving surgical exposure of the common carotid artery in the neck, insertion of a sheath to enable direct carotid access, and flow reversal — blood is pumped from the carotid artery to the femoral vein during stenting, keeping embolic debris away from the brain. TCAR avoids the risk of embolic events from femoral-to-carotid CAS catheter manipulation around an atherosclerotic aortic arch. Registry data suggest TCAR has lower stroke rates than transfemoral CAS in higher-risk patients. TCAR is appropriate for patients at intermediate surgical risk who are not suitable for standard CEA but have accessible carotid anatomy.

The benefits of carotid artery intervention are quantified by decades of landmark trial evidence and represent some of the strongest evidence in vascular and cerebrovascular medicine:

• Major stroke risk reduction in symptomatic high-grade stenosis: The NASCET trial (North American Symptomatic Carotid Endarterectomy Trial) demonstrated a 17% absolute risk reduction (ARR) in 5-year ipsilateral stroke rate for symptomatic 70–99% stenosis (26% risk with medical treatment alone vs 9% with CEA). The number needed to treat (NNT) of approximately 6 makes CEA one of the most cost-effective stroke prevention interventions available. The ECST trial confirmed equivalent findings using its own measurement methodology.
• Greatest benefit with urgent surgery: Landmark data from the Oxford Vascular Study (OXVASC) and subsequent analyses show that the benefit of CEA over medical therapy is highest in the first 2 weeks after TIA or minor stroke. Stroke risk without surgery is approximately 10–20% in the first 72 hours after a TIA from carotid disease; early CEA dramatically reduces this risk. Delaying surgery beyond 14 days substantially reduces — and may eliminate — the net benefit of intervention.
• Moderate symptomatic stenosis benefit: For 50–69% symptomatic stenosis, the 5-year ARR from CEA is approximately 4.6% (NASCET). Benefit is concentrated in specific subgroups: males, patients over 75 years, those with hemispheric events (not ocular TIA), cortical infarction on CT, irregular plaque morphology, and contralateral ICA occlusion. Careful patient selection maximises net benefit in this group.
• Cranial nerve injury avoidance compared to repeat surgery: CEA at initial presentation is associated with lower cranial nerve injury rates (approximately 4–7% transient, 1–2% permanent) than re-do carotid surgery, supporting early definitive treatment when indicated rather than watchful waiting.
• Long-term durability: CEA is highly durable, with ipsilateral stroke-free survival rates of over 90% at 5 years and 85% at 10 years for appropriately selected patients who also receive intensive medical secondary prevention (aspirin, statin, antihypertensive therapy).

Carotid surgery carries specific risks that must be carefully weighed against the benefits of stroke prevention. The overall perioperative safety benchmark defines the limits within which surgery is beneficial:

• 30-day stroke and death rate (the perioperative benchmark): The net benefit of CEA for symptomatic stenosis is only realised if the combined 30-day stroke and death rate remains below 3% for symptomatic stenosis and below 1.5–2% for asymptomatic stenosis. NICE and the European Stroke Organisation mandate this audit standard. Patients should ask their surgeon and centre for their audited complication rates before consenting.
• Perioperative stroke: Occurs in 1–2% of CEA procedures at specialist centres. Most are embolic events occurring during plaque dissection or from intraoperative carotid thrombosis during clamping. Neurological monitoring with EEG or TCD and selective shunting reduce, but do not eliminate, this risk. Postoperative stroke can also occur in the first 24–48 hours from carotid thrombosis or local haematoma compressing the repaired artery.
• Myocardial infarction: Occurs in approximately 1–2% of CEA procedures, reflecting the high prevalence of coexistent coronary artery disease in patients with carotid atherosclerosis. Preoperative cardiac assessment and optimisation of antiplatelet and statin therapy reduce cardiac risk.
• Cranial nerve injuries: The hypoglossal nerve (tongue deviation), vagus nerve (hoarseness, dysphagia), and marginal mandibular branch of the facial nerve are at risk during carotid dissection. Transient cranial nerve dysfunction from retraction occurs in 4–7% and typically resolves within 3–6 months. Permanent injury occurs in 1–2%. Hypoglossal nerve injury causes ipsilateral tongue deviation; vagal injury causes hoarse voice and aspiration risk; marginal mandibular injury causes ipsilateral lower lip weakness.
• Neck wound haematoma: Haematoma in the neck wound after CEA occurs in 2–5% and may rapidly compromise the airway due to tracheal compression if large. Urgent surgical re-exploration is required for expanding haematomas. Close monitoring for the first 6–12 hours postoperatively is essential; some centres manage the first night in a HDU or monitored bed.
• Hyperperfusion syndrome: Occurs in under 1% of CEA patients, typically those with severe contralateral occlusion or bilateral high-grade stenosis who have chronic cerebrovascular autoregulatory impairment. After restoration of normal flow, previously maximally dilated cerebral vessels cannot re-autoregulate, resulting in cerebral oedema, headache, seizures, and haemorrhagic transformation. Strict postoperative blood pressure control (systolic below 150 mmHg) is essential for high-risk patients.
• CAS-specific risks — higher minor stroke rate: CAS consistently shows a higher rate of minor periprocedural stroke than CEA across the major RCTs (ICSS: 5% vs 3.4%; CREST: 4.1% vs 2.3%). Many of these strokes are subclinical on MRI diffusion sequences, but are associated with cognitive impairment in some studies. CAS carries lower rates of MI and cranial nerve injury than CEA.

Carotid artery surgery addresses the mechanical stenosis but does not cure the underlying systemic atherosclerotic disease. Lifelong secondary prevention and surveillance are essential:

Postoperative monitoring: Most patients are observed for 24 hours postoperatively with neurological and cardiovascular monitoring. Blood pressure is carefully controlled to reduce risk of wound haematoma, hyperperfusion, and cerebral haemorrhage. Early mobilisation within 24 hours is standard. Aspirin is continued through the perioperative period and indefinitely thereafter.

Duplex carotid ultrasound surveillance: Postoperative duplex scan is performed at 4–6 weeks as a baseline (accounting for postoperative changes), then at 6 months and annually for 2 years, and subsequently every 2 years indefinitely. Surveillance identifies restenosis (which occurs in 1–5% after CEA with patch and 5–15% after primary closure) and allows timely intervention before symptom recurrence. Following CAS, duplex surveillance is particularly important as in-stent restenosis rates are higher at 10–20%.

Contralateral carotid monitoring: Patients with bilateral carotid disease require continued surveillance of the contralateral side, as the untreated carotid may progress to a degree requiring intervention. Annual duplex assessment of the contralateral ICA is standard in high-risk patients.

Secondary prevention medical therapy: All patients after carotid intervention require lifelong optimal medical prevention: aspirin 75–100 mg daily indefinitely; high-intensity statin (atorvastatin 40–80 mg) with LDL target below 1.8 mmol/L; antihypertensive therapy targeting blood pressure below 130/80 mmHg; and smoking cessation with formal support if required. Dual antiplatelet therapy (aspirin plus clopidogrel) is typically recommended for 1–6 months after CAS.

Driving and lifestyle: Most patients can resume driving 4 weeks after CEA if there are no new neurological symptoms. Patients who have had a TIA or stroke may face separate DVLA-mandated driving restrictions (1 month licence revocation for TIA in most European jurisdictions). Return to work is typically possible within 2–4 weeks for sedentary roles and 4–6 weeks for physical work.

The cost of carotid artery intervention varies by procedure type, healthcare system, and country. Understanding cost differences is particularly relevant for international patients seeking stroke prevention treatment abroad.

• CEA costs by country: In the United States, elective CEA typically costs USD 15,000–45,000 including surgeon fees, anaesthesia, hospital stay (typically 1–2 days), preoperative imaging, and postoperative care. In the UK, NHS CEA is covered at no direct cost; private sector costs range from GBP 6,000–18,000. In India at accredited vascular surgical centres, CEA costs approximately INR 100,000–300,000 (USD 1,200–3,600). In Thailand, CEA at internationally accredited hospitals costs USD 6,000–15,000.
• CAS costs: Transfemoral carotid artery stenting is generally more expensive than CEA in the same healthcare system due to the cost of the stent and embolic protection device hardware. In the US, CAS costs USD 20,000–60,000. The additional equipment cost is partially offset by shorter hospital stay (typically overnight or day case). In India, CAS costs USD 3,000–7,000 including the stent device.
• TCAR costs: As a hybrid procedure combining surgical and endovascular expertise and equipment, TCAR carries the highest cost among the three approaches — typically USD 25,000–70,000 in the US. It is increasingly covered by Medicare and private insurers in the US for appropriate indications.
• Preoperative imaging: CT carotid angiography (approximately USD 1,500–3,000 in the US) or MR angiography (USD 2,000–4,000) is essential for procedural planning and adds to total cost. In India, CT angiography costs approximately INR 5,000–15,000 (USD 60–180) at major hospitals.
• Long-term medication costs: Lifelong antiplatelet and statin therapy is inexpensive with generic formulations — generic aspirin and generic atorvastatin cost less than USD 10 per month in most countries — but represents a necessary and ongoing element of the total cost of stroke prevention after carotid intervention.

The choice between surgical intervention and alternative strategies must be individualised, guided by the degree and symptom status of stenosis, patient comorbidities, and the patient's own risk tolerance and values:

• Optimal Medical Therapy (OMT) alone: The most important comparator to carotid intervention, particularly for asymptomatic patients. Modern OMT — combining high-intensity statins, dual antiplatelet therapy for the first month after TIA, single antiplatelet therapy thereafter, strict blood pressure control, and intensive lifestyle modification — has reduced the annual ipsilateral stroke rate in asymptomatic carotid stenosis to approximately 0.5–1.0% per year in recent registries and trial control arms (compared to 2–3% historically). This improvement in medical therapy substantially narrows the window of benefit for prophylactic surgery in asymptomatic patients. OMT alone is appropriate for asymptomatic patients at high surgical risk, for those with moderate (50–69%) asymptomatic stenosis, and for patients who do not wish surgery after full informed discussion of the evidence.
• Carotid Artery Stenting (CAS) as an alternative to CEA: For symptomatic stenosis in patients under 70 years without high-risk anatomy for CAS (severe arch calcification, severe vessel tortuosity), CAS is an acceptable alternative to CEA with equivalent long-term stroke prevention and lower rates of MI and cranial nerve injury. CAS is the preferred approach in patients with prior neck surgery or irradiation, and in those with medical comorbidities that substantially elevate surgical risk.
• Transcarotid Arterial Revascularisation (TCAR): The intermediate option between CEA and CAS, offering the flow reversal neuroprotection of a direct carotid approach with the minimally invasive advantages of endovascular stenting. TCAR is appropriate for high-surgical-risk patients in whom the benefit of intervention over OMT still outweighs risk, but where standard CEA morbidity is predicted to be excessive. FDA approval and CMS coverage in the US have expanded TCAR availability significantly.
• Watchful waiting with accelerated imaging surveillance: For asymptomatic patients with lower degrees of stenosis (60–79%) or those in whom the 5-year competing risk from cardiac or other disease makes long-term stroke prevention less relevant, a strategy of 6–12 monthly duplex surveillance with OMT and intervention only if stenosis progresses or symptoms develop is clinically appropriate and avoids procedural risk entirely.